Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
5
|
| pubmed:dateCreated |
1994-10-6
|
| pubmed:abstractText |
HA1004, an isoquinolinesulfonamide and a cyclic nucleotide-dependent protein kinase inhibitor, is an intracellular calcium antagonist that produces vascular smooth muscle (VSM) relaxation in vitro. We studied the hemodynamic effects of intravenous (i.v.) infusions of HA1004 (0.1-2.0 mg/kg) in vivo in 8 newborn lambs, at rest and during pulmonary hypertension induced either by the i.v. infusion of U46619, a thromboxane A2 (TXA2) mimic, or by alveolar hypoxia. For comparison, we also studied the hemodynamic effects of i.v. infusions of nifedipine (15 and 40 micrograms/kg/min), a calcium entry blocker. At rest, HA1004 produced slight but significant changes in pulmonary and systemic arterial pressure (PAP, SAP) and pulmonary and systemic vascular resistances (PVR, SVR) (p < 0.05). During pulmonary hypertension induced by U46619, HA1004 decreased PAP 12-23% and PVR 9-33% (p < 0.05), whereas SAP decreased 7% and SVR decreased 14% at only one dose (p < 0.05). During pulmonary hypertension induced by alveolar hypoxia, HA1004 decreased PAP 6-32% and PVR 11-30% (p < 0.05), whereas SAP decreased 15% only at the highest dose (p < 0.05). Linear regression analysis of the pooled data demonstrated that HA1004 caused selective pulmonary vasodilation during pulmonary hypertension. Nifedipine decreased PAP 6 and 14% and SAP 5 and 17% during pulmonary hypertension. In newborn lambs with pulmonary hypertension, HA1004, an intracellular calcium antagonist, is more selective and potent than nifedipine, a calcium entry blocker, in decreasing PAP and therefore may be useful in treatment of children with pulmonary hypertension.
|
| pubmed:grant | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/15-Hydroxy-11 alpha,9...,
http://linkedlifedata.com/resource/pubmed/chemical/Calcium Channel Blockers,
http://linkedlifedata.com/resource/pubmed/chemical/Isoquinolines,
http://linkedlifedata.com/resource/pubmed/chemical/N-(2-guanidinoethyl)-5-isoquinolines...,
http://linkedlifedata.com/resource/pubmed/chemical/Nifedipine,
http://linkedlifedata.com/resource/pubmed/chemical/Prostaglandin Endoperoxides...,
http://linkedlifedata.com/resource/pubmed/chemical/Protein Kinase Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Sulfonamides,
http://linkedlifedata.com/resource/pubmed/chemical/Thromboxane A2
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
May
|
| pubmed:issn |
0160-2446
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
23
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
806-13
|
| pubmed:dateRevised |
2007-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:7521465-15-Hydroxy-11 alpha,9...,
pubmed-meshheading:7521465-Animals,
pubmed-meshheading:7521465-Animals, Newborn,
pubmed-meshheading:7521465-Anoxia,
pubmed-meshheading:7521465-Calcium Channel Blockers,
pubmed-meshheading:7521465-Hemodynamics,
pubmed-meshheading:7521465-Hypertension, Pulmonary,
pubmed-meshheading:7521465-Infusions, Intravenous,
pubmed-meshheading:7521465-Isoquinolines,
pubmed-meshheading:7521465-Muscle Relaxation,
pubmed-meshheading:7521465-Nifedipine,
pubmed-meshheading:7521465-Prostaglandin Endoperoxides, Synthetic,
pubmed-meshheading:7521465-Protein Kinase Inhibitors,
pubmed-meshheading:7521465-Pulmonary Alveoli,
pubmed-meshheading:7521465-Regression Analysis,
pubmed-meshheading:7521465-Sheep,
pubmed-meshheading:7521465-Sulfonamides,
pubmed-meshheading:7521465-Thromboxane A2
|
| pubmed:year |
1994
|
| pubmed:articleTitle |
HA1004, an intracellular calcium antagonist, selectively attenuates pulmonary hypertension in newborn lambs.
|
| pubmed:affiliation |
Cardiovascular Research Institute, University of California at San Francisco, 94143.
|
| pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.
|